Skip to main content
SpringerLink
Log in

Clindamycin bioavailability from clindamycin-2-palmitate and clindamycin-2-hexadecylcarbonate in man

  • Published:
Journal of Pharmacokinetics and Biopharmaceutics Aims and scope Submit manuscript

Abstract

To determine the bioavailability of clindamycin from the microbiologically inactive clindamycin-2-palmitate and clindamycin-2-hexadecylcarbonate in man, a three-way crossover study was conducted with oral administration of the two esters and clindamycin hydrochloride. In each case, serum clindamycin bioactivity concentrations were fitted to a one-compartment open model with an initial lag time. Analysis of variance of measured quantities (serum concentrations and urinary excretion) and of derived pharmacokinetic parameters showed that for every comparison except maximum serum concentrations clindamycin-2-palmitate was not significantly different (at p=0.05) from clindamycin hydrochloride. Clindamycin-2-hexadecylcarbonate gave significantly different values from those for the hydrochloride in all cases except the rate constant and half-life for elimination from the serum. The palmitate was the superior ester and was bioequivalent to the hydrochloride in man.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. J. E. Gray, A. Purmalis, B. Purmalis, and J. Mathews. Ultrastructural studies of the hepatic changes brought about by clindamycin and erythromycin in animals.Toxicol. Appl. Pharmacol. 19: 217–233 (1971).

    Article  CAS  PubMed  Google Scholar 

  2. J. E. Gray, R. N. Weaver, J. A. Bollert, and E. S. Feenstra. The oral toxicity of clindamycin in laboratory animals.Toxicol. Appl. Pharmacol. 21: 516–531 (1972).

    Article  CAS  PubMed  Google Scholar 

  3. T. F. Brodasky, A. D. Argoudelis, and T. E. Eble. The characterization and thin-layer chromatographic quantitation of the human metabolite of 7-deoxy-7(S) chlorolincomycin (U-21, 251F).J. Antibiot. 21: 327–333 (1968).

    Article  CAS  PubMed  Google Scholar 

  4. J. G. Wagner, E. Novak, N. C. Patel, C. G. Chidester, and W. L. Lummis. Absorption, excretion and half-life of clinimycin in normal adult males.Am. J. Med. Sci. 256: 25–37 (1968).

    Article  CAS  PubMed  Google Scholar 

  5. R. F. McGehee, Jr., C. B. Smith, C. Wilcox, and M. Finland. Comparative studies of antibacterial activityin vitro and absorption and excretion of lincomycin and clinimycin.Am. J. Med. Sci. 256: 279–292 (1968).

    Article  CAS  PubMed  Google Scholar 

  6. J. E. Cimino and P. M. Tierno, Jr. Hemodialysis properties of clindamycin (7-chloro-7-deoxylincomycin).Appl. Microbiol. 17: 446–448 (1969).

    CAS  PubMed Central  PubMed  Google Scholar 

  7. B. R. Meyers, K. Kaplan, and L. Weinstein. Microbiological and pharmacological behavior of 7-chlorolincomycin.Appl. Microbiol. 17: 653–657 (1969).

    CAS  PubMed Central  PubMed  Google Scholar 

  8. M. A. Plott and H. Roth. Penetration of clindamycin into synovial fluid.Clin. Pharmacol. Therap. 11: 577–580 (1970).

    CAS  Google Scholar 

  9. M. J. Taraszka. Absorption of clindamycin from the buccal cavity.J. Pharm. Sci. 59: 873–874 (1970).

    Article  CAS  PubMed  Google Scholar 

  10. E. Novak, J. G. Wagner, and D. J. Lamb. Local and systemic tolerance, absorption and excretion of clindamycin hydrochloride after intramuscular administration.Internat. J. Clin. Pharmacol. Therap. Toxicol. 3: 201–208 (1970).

    CAS  Google Scholar 

  11. R. M. DeHaan, C. M. Metzler, D. Schellenberg, W. D. VandenBosch, and E. L. Masson. Pharmacokinetic studies of clindamycin hydrochloride in humans.Internat. J. Clin. Pharmacol. Therap. Toxicol. 6: 105–119 (1972).

    CAS  Google Scholar 

  12. O. Kitamoto, K. Fukaya, and G. Tomori. Pharmacokinetics of the antimicrobial agent clindamycin.Nippon Kagaku Ryohogakukai Zasshi 17: 822–827 (1969).

    CAS  Google Scholar 

  13. F. F. Sun. Disposition of clindamycin in rat and dog.Fed. Proc. 29: 677 (1970).

    Google Scholar 

  14. K. Matsui. Studies on the metabolism of clindamycin.Nippon Kagaku Ryohogakukai Zasshi 18: 1025–1030 (1970).

    Google Scholar 

  15. M. J. Taraszka. Transfer of clindamycin and 1′-demethyl-4′-depropyl-4′-pentylclindamycin by the cannulated-everted rat gut.J. Pharm. Sci. 60: 946–948 (1971).

    Article  CAS  Google Scholar 

  16. A. A. Sinkula, W. Morozowich, and E. L. Rowe. The chemical modification of clindamycin: Synthesis and evaluation of selected esters. Abstracts, Basic Pharmaceutics Section, APhA, 117th Meeting, Washington, D.C., April 12–17, 1970.

  17. C. M. Metzler. A brief introduction to nonlinear least squares estimation. Compilation of Symposia Papers, APhA Academy of Pharmaceutical Sciences, 1970, p. 380.

  18. M. J. Taraszka. Relative enzymatic hydrolysis rates of lincomycin esters I: Soluble esters.J. Pharm. Sci. 60: 1414–1417 (1971).

    Article  CAS  PubMed  Google Scholar 

  19. R. M. DeHaan, D. Schellenberg, W. D. VandenBosch, and M. H. Maile. Clindamycin palmitate in healthy men: General tolerance and effect on stools.Curr. Therap. Res. Clin. Exptl. 14: 81–90 (1972).

    CAS  Google Scholar 

  20. R. M. DeHaan, W. D. VandenBosch, and C. M. Metzler. Clindamycin serum concentrations after administration of clindamycin palmitate with food.J. Clin. Pharmacol. 12: 205–211 (1972).

    CAS  Google Scholar 

  21. N. Levin and P. J. Collipp. Absorption and tolerance of clindamycin-2-palmitate in infants below 6 months of age.Curr. Therap. Res. Clin. Exptl. 12: 648–657 (1970).

    Google Scholar 

  22. R. M. DeHaan and D. Schellenberg. Clindamycin palmitate flavored granules. Multidose tolerance, absorption, and urinary excretion study in healthy children.J. Clin. Pharmacol. 12: 74–83 (1972).

    CAS  Google Scholar 

  23. W. M. Pugliese, D. N. Mesches, J. Wiersum, C. L. Henriquez, III, and J. F. Krivda. Double blind study: Cleocin palmitate and erythrocin pediatric in otitis media in children.Curr. Therap. Res. Clin. Exptl. 14: 31–34 (1972).

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Laboratories, The Upjohn Company, 49001, Kalamazoo, Michigan

    Arlington A. Forist, Ray M. DeHaan & Carl M. Metzler

Authors
  1. Arlington A. Forist
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ray M. DeHaan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carl M. Metzler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Forist, A.A., DeHaan, R.M. & Metzler, C.M. Clindamycin bioavailability from clindamycin-2-palmitate and clindamycin-2-hexadecylcarbonate in man. Journal of Pharmacokinetics and Biopharmaceutics 1, 89–98 (1973). https://doi.org/10.1007/BF01059623

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01059623

Key words

Search

Navigation